DR-5 and DLL-4 mAb Functionalized SLNs of Gamma-Secretase Inhibitors- An Approach for TNBC Treatment

Mamta Kumari ¹ , Praveen T. Krishnamurthy ¹ * , Sai kiran S. S. Pinduprolu ¹, Piyongsola Sola ¹

Cited by CrossRef: 8

1- Choi H, Kim K. Theranostics for Triple-Negative Breast Cancer. Diagnostics. 2023;13(2):272 [Crossref]

2- Jiang N, Hu Y, Wang M, Zhao Z, Li M. The Notch Signaling Pathway Contributes to Angiogenesis and Tumor Immunity in Breast Cancer. BCTT. 2022;Volume 14:291 [Crossref]

3- Li J, Goh E, He J, Li Y, Fan Z, Yu Z, Yuan P, Liu D. Emerging Intrinsic Therapeutic Targets for Metastatic Breast Cancer. Biology. 2023;12(5):697 [Crossref]

4- Kumari M, Acharya A, Krishnamurthy P. Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics. Beilstein J Nanotechnol. 2023;14:912 [Crossref]

5- Marques A, Costa P, Velho S, Amaral M. Lipid Nanoparticles Functionalized with Antibodies for Anticancer Drug Therapy. Pharmaceutics. 2023;15(1):216 [Crossref]

6- McHenry P, Prosperi J. Proteins Found in the Triple-Negative Breast Cancer Secretome and Their Therapeutic Potential. IJMS. 2023;24(3):2100 [Crossref]

7- Feng M, Santhanam R, Xing H, Zhou M, Jia H. Inhibition of γ-secretase/Notch pathway as a potential therapy for reversing cancer drug resistance. Biochemical Pharmacology. 2024;220:115991 [Crossref]

8- Marracino L, Fortini F, Bouhamida E, Camponogara F, Severi P, Mazzoni E, Patergnani S, D’Aniello E, Campana R, Pinton P, Martini F, Tognon M, Campo G, Ferrari R, Vieceli Dalla Sega F, Rizzo P. Adding a “Notch” to Cardiovascular Disease Therapeutics: A MicroRNA-Based Approach. Front Cell Dev Biol. 2021;9 [Crossref]

9- Yang R, Li Y, Wang H, Qin T, Yin X, Ma X. Therapeutic progress and challenges for triple negative breast cancer: targeted therapy and immunotherapy. Mol Biomed. 2022;3(1) [Crossref]